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Abstract
Background: Chronic fatigue syndrome (CFS) also known as myalgic encephalomyelitis (ME) is relatively
common in young people and causes significant disability. Graded exercise therapy (GET) and activity
management are recommended by the National Institute for Health and Care Excellence (NICE) despite a
limited evidence-base for either treatment in paediatric CFS/ME. This paper reports on feasibility and
acceptability measures from the feasibility phase of the ongoing MAGENTA randomised controlled trial (RCT)
investigating GET versus activity management for young people with CFS/ME.
Methods: Setting: Three specialist secondary care National Health Service (NHS) Paediatric CFS/ME services
(Bath, Cambridge and Newcastle).
Participants: Young people aged 8–17 years with a diagnosis of mild to moderate CFS/ME. Young people
were excluded if they were severely affected, referred to cognitive behavioural therapy (CBT) at initial
assessment or unable to attend clinical sessions.
Interventions: GET and activity management delivered by physiotherapists, occupational therapists, nurses and
psychologists. Families and clinicians decided the number (typically 8–12) and frequency of appointments
(typically every 2–6 weeks).
Outcome Measures: Recruitment and follow-up statistics. We used integrated qualitative methodology to
explore the feasibility and acceptability of the trial processes and the interventions.
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Results: 80/161 (49.7%) of eligible young people were recruited at two sites between September 2015 and
August 2016, indicating recruitment to the trial was feasible. Most recruitment (78/80; 97.5%) took place at
one centre. Recruitment consultations, online consent and interventions were acceptable, with less than 10%
in each arm discontinuing trial treatment. Response rate to the primary outcome (the SF36-PFS at 6 months)
was 91.4%. Recruitment, treatment and data collection were not feasible at one centre. The site was
withdrawn from the study.
In response to data collected, we optimised trial processes including using Skype for recruitment discussions;
adapting recruiter training to improve recruitment discussions; amending the accelerometer information
leaflets; shortening the resource use questionnaires; and offering interventions via Skype. These amendments
have been incorporated into the full trial protocol.
Conclusions: Conducting an RCT investigating GET versus activity management is feasible and acceptable for
young people with CFS/ME.
Trial registration: ISRCTN23962803 https://doi.org/10.1186/ISRCTN23962803, date of registration: 03 September
2015
Keywords: Chronic fatigue syndrome, Myalgic encephalomyelitis, CFS/ME, Graded exercise therapy, Activity
management, Feasibility study, Randomisation controlled trial, Qualitative research
Background
Paediatric chronic fatigue syndrome (CFS) also known
as myalgic encephalomyelitis (ME) is relatively com-
mon, with an estimated prevalence between 1 and
2.4% in adolescence [1, 2]. It is a complex, serious
and disabling condition that includes a range of
symptoms such as debilitating fatigue, muscle and
joint pain, flu-like symptoms, sleep difficulties and
nausea [3]. It has a significant impact on young peo-
ple’s lives; most (62%) of those attending specialist
services attend only 2 days a week of school or less
[4], over half are bed-bound at some stage [5] and af-
fected young people give up social activities and hob-
bies [6].
The National Institute for Health and Care Excel-
lence (NICE) recommends that young people with
CFS/ME are offered either graded exercise therapy
(GET), activity management or cognitive behavioural
therapy (CBT) [7]. GET stabilises physical activity
levels, before gradually increasing at a manageable
rate. Activity management establishes a baseline for
all activity which is then increased [7, 8]. In adoles-
cents, this is mainly cognitive activities, such as
school/homework, time on-line and social activities.
CBT includes behavioural elements, but also uses
cognitive approaches to support psychological needs
and encourage behaviour change [9]. There is some
evidence for the effectiveness of CBT in young
people with CFS/ME [10–12]; however, there is lim-
ited evidence for the effectiveness of GET in this
population [13]. In adults, when added to standard
medical care, GET is moderately effective in redu-
cing fatigue and improving physical function [14].
MAGENTA is a randomised controlled trial (RCT)
to investigate the effectiveness and cost-effectiveness
of GET versus activity management in outpatient
treatment of paediatric CFS/ME. The study is evaluat-
ing complex interventions [15]; the interventions have
several interacting components, and there is a degree
of flexibility in how the interventions can be delivered.
MAGENTA includes process evaluation [15], includ-
ing mediation analysis and testing trial processes such
as a novel method of online consent. Prior to the full-
scale RCT, we carried out a feasibility study [15]. This
was to determine the feasibility of trial processes and
whether the trial and interventions were acceptable to
young people with CFS/ME. Findings from feasibility
studies can be used to improve processes for the full
trial, for example improving recruitment consulta-
tions, refining outcome measures and guiding the de-
livery of interventions [16–18]. If there were no
substantial changes to trial methodology or the deliv-
ery of interventions, we planned to use data from the
feasibility phase in an adequately powered RCT. In
this paper, we report the results from the feasibility
phase of the trial.
Aims and objectives
To ascertain the feasibility and acceptability of con-
ducting an RCT to investigate the effectiveness and
cost-effectiveness of GET compared to activity man-
agement for paediatric CFS/ME with the aim of
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moving seamlessly to a full RCT. Specific objectives
were to:
1. Assess the number of young people who were:
eligible, approached, recruited and retained in the
first six months of the study.
2. Identify barriers and facilitators to recruitment.
3. Explore issues of retention and understand why
people drop out of the study.
4. Assess the acceptability of intervention.
5. Evaluate the fidelity of intervention delivery.
6. Assess the feasibility and acceptability of using
accelerometers.
Methods
Design
We conducted a feasibility study with integrated
qualitative methods. So long as the interventions
and study processes were not significantly changed
on proceeding to the full trial, this initial stage
would be considered as an internal pilot and the
outcome data collected included in the main trial
analysis. Full details of the methods can be found
in the published protocol [19] and are summarised
below.
Setting
Recruitment to the feasibility study occurred between
September 2015 and August 2016 at three Specialist
Paediatric CFS/ME National Health Service (NHS) ser-
vices: Bath, Newcastle and Cambridge. Combined, these
services provide assessment and treatment for more than
380 young people each year.
Participants
Young people were screened for eligibility at their initial
clinical assessment carried out by a CFS/ME clinical spe-
cialist (including paediatricians and psychologists).
Young people were eligible if they:
 Had a diagnosis of mild to moderate CFS/ME. [7]
 Were aged between 8–17 years.
And excluded if they:
 Were severely affected (unable to do activity for
themselves, only able to carry out minimal daily
tasks, or had severe cognitive difficulties and depend
on a wheelchair for mobility. [7])
 Referred to CBT at their first clinical assessment.
 Were unable to attend clinical sessions.
Procedure
Assessing clinicians identified potential participants,
provided an overview of the study and gained
assent/consent to contact from those families inter-
ested in learning more about the study. Full recruit-
ment discussions, typically carried out by a
specialist nurse, were conducted face-to-face or via
telephone/Skype. At the outset, the recruiter con-
firmed that the families were happy for the discus-
sion to take place and happy for it to be audio-
recorded. They continued to discuss information
about the trial: study design, interventions, partici-
pant burden and the potential benefits and risks.
From the outset, our aim was to continue seam-
lessly into a full trial if this RCT was shown to be
both feasible and acceptable. Participants were
therefore informed that their outcome data would
be used in the full trial if the RCT was shown to be
feasible. Families wishing to consent to the study
could do so by completing online consent forms via
the REDCap (Research Electronic Data Capture)
hosted at the University of Bristol [20]. Young
people under the age of 16 provided assent and
those over 16 provided consent. We also obtained
consent from carers/parents. Paper consent forms
were used for face-to-face recruitment consultations.
Consenting participants were then randomised,
using the automated web service operated by the
Bristol Randomised Trials Collaboration. Allocation
(1:1) used minimisation to facilitate balance by age
and gender, and retained a random component to
prevent accurate prediction of allocation. Because of
the nature of the intervention, it was not practical
to keep either the family or the clinical service blind
to treatment allocation. Participants were informed
of their allocation either at the end of the recruit-
ment consultation, or at a later date by phone.
Figure 1 describes the trial and treatment processes.
Sample size
We calculated that a sample size of approximately
100 participants would provide sufficient information
to inform a full trial. Recruitment of 100 participants
from 430 young people assessed for eligibility would
give a 95% confidence interval of the order of 20–
28% for estimating a true recruitment rate (rate of
those assessed found to be eligible and subsequently
consented) of 24%. Twenty-four percent is reason-
able, based on previous RCTs exploring treatment
for paediatric CFS/ME [21].
Interventions
In both arms, clinicians could provide routine advice
about sleep, medication use and symptom control.
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Families and clinicians decided upon the number of
follow-up sessions (typically between 8 and 12) and
the frequency of appointments (typically every 2–6
weeks). The interventions were delivered in second-
ary care outpatient clinics, delivered face-face in the
hospital setting or via Skype (see section “The ac-
ceptability (satisfaction and adherence) of
intervention”).
Graded exercise therapy
Trained GET therapists (physiotherapists, occupa-
tional therapists, nurses or psychologists) initially
assessed the young person’s physical activity and col-
laboratively recommended a tailored treatment plan.
This started with identifying a “baseline” of physical
activity. The baseline is the average level of physical
activity that a young person does. It is normally about
half of what they can do on a good day. Establishing a
baseline, means the young person will do the same
level of physical activity each day, avoiding “payback”
or an increase in symptoms which usually occurs after
they have done too much. It therefore avoids the
boom-bust pattern of exercise (doing too much,
followed by an increase in symptoms and doing not
Fig. 1 Study flow diagram detailing participant flow through clinical and research processes. From the MAGENTA protocol [19]
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very much) that is typical of CFS/ME. In addition,
therapists calculated the young person’s “maximum”
heart rate (220 minus their age). At the start of treat-
ment, young people were advised to try and ensure
physical activity levels were low enough so heart rate
did not increase to more than 40–50% of this max-
imum heart rate. Clinicians taught young people how
to manually measure their heart rate. Younger chil-
dren and those unable to manually take their heart
rate, were offered a Fitbit Charge HR [22] to assist this
(subject to availability).
Once the baseline level of activity was achieved and
maintained, the young person was supported to grad-
ually increase physical activity, increasing activity levels
by 10–20% a week [7].
Activity management
Activity management was delivered by specialist
CFS/ME clinicians (occupational therapists, physio-
therapists, nurses and psychologists). The clinician
assessed the participant’s current levels of activity,
including cognitive activities (school work, reading,
socialising and screen time (phone, laptop, TV,
games)), emotional activities (for example, having an
argument) and physical activities. The clinician and
participant then agreed a “baseline” of activity: a
daily sustainable level of activity, typically the aver-
age daily amount of activity that the young person
reported at assessment. Young people were taught
how to record the total number of minutes spent
each day doing different levels of activity (high-en-
ergy and low-energy) using either paper diaries or
the “ActiveME” digital App. When participants
achieved a “baseline” of all activity (cognitive/phys-
ical/emotional), they were supported to gradually in-
crease activity by 10–20% each week.
Data collection
Screening, eligibility, consent and randomisation
We recorded the number of potentially eligible partic-
ipants attending the clinic, the number assessed for
eligibility, the number of eligible patients who con-
sented (and the reasons why families declined) and
the number who were randomised. We also recorded
the number of participants who discontinued treat-
ment and the number who completed outcome mea-
sures. These statistics were presented in Consolidated
Standards of Reporting Trials (CONSORT) flow
charts.
Patient-reported outcome measures
At baseline, six and 12 months, the following data
were collected from participants via self-report
questionnaires: physical function (SF36-PFS) [23];
fatigue (Chalder scale) [24]; educational attendance
(self-report school or home tuition); mood (Hospital
Anxiety and Depression Scale) [25]; (Spence Chil-
dren’s Anxiety Scale) [26]; pain (visual analogue
scale) [27]; (Clinical Global Impression Scale) [14];
general health-related quality of life (EQ-5D-Y) [28].
The anticipated primary outcome for the main trial
comparison was the SF36-PFS at six months.
At baseline, six and 12 months, parents/carers were
asked to complete questions about their child’s
healthcare resource use, and the Work Productivity
and Activity Impairment Questionnaire: General
Health (WPAI:GH) to capture the effect of their
child’s health problems on their ability to work and
perform regular activities [29].
Baseline participant self-report questionnaires were
collected on paper forms prior to randomisation. All
other self-report questionnaires were completed re-
motely via REDCap, a secure system used by many
institutions for large multicentre studies. Participants
submitted their questionnaire data directly to the
REDcap system. If questionnaires were not com-
pleted, a researcher contacted the family and asked
to complete the primary outcome data over the
telephone.
Accelerometer
Participants in both trial arms were asked to wear
an accelerometer (Actigraph GT3X+, Actigraph LLC
Florida) to measure physical activity for seven days
within 1 month of randomisation and at three- and
six-month follow-up. Accelerometers are small,
match box-sized devices that measure physical activ-
ity. The device is attached to a waist band and sits
on the hip. The accelerometer data were processed
to identify the number of participants who supplied
valid data. Data were deemed valid based on the
procedures used in the International Children’s Ac-
celerometer Database (ICAD) if participants wore
the accelerometer for at least two weekdays and at
least one weekend day out of the seven, for at least
500 min per day [30].
Quantitative data analysis
Baseline continuous data were summarised by median
and interquartile range and categorical data by counts
and percentages. No data analysis of outcome measures
was performed at the feasibility stage because the data
were to be retained for use in the main trial.
Integrated qualitative methodology
Recruitment consultations
Recruitment consultations were routinely audio-recorded
to explore information provision, and the acceptability
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of trial methodology (e.g. randomisation). During the
feasibility phase, three recruiters for the three sites re-
ceived one-to-one recruitment training (1.5 to 4.5 h
each) from a member of the research team (LB).
Training was based on the communication strategies
shown to be effective in trials of adults in terms of
engaging with treatment preferences and conveying
equipoise [17, 31–33]. Recruitment consultations that
highlighted good practice or potential barriers to re-
cruitment were transcribed and discussed with re-
cruiters at each training session. A “Tips for
recruitment and informed consent” document was de-
veloped and given to each recruiter as a guide for
good practice.
Participant interviews
Semi-structured interviews were conducted with par-
ticipants and parents who had consented to the trial
to understand their views and experiences of trial
processes. This included acceptability of patient in-
formation, treatment interventions and use of accel-
erometers/heart rate monitors. Participants were
offered a choice of interview location: at home, in
the hospital, via skype or by telephone. A checklist
of topics was developed from a previous trial carried
out with young people with CFS/ME [34]. This was
used to guide discussion, but those participating
were encouraged to raise issues they felt to be im-
portant. Interviews lasted between 15 and 60 min.
They were audio-recorded with consent, and tran-
scribed verbatim.
Qualitative data analysis
Qualitative data analysis was an on-going, and iterative
process that started soon after data collection began,
using techniques of constant comparison to inform
further sampling and data collection [35]. Recruitment
consultations were purposively selected for analysis on
a month by month basis, representing a mix of fam-
ilies who accepted and declined randomisation. Atten-
tion was paid to consultations in which families
declined the trial, to understand the views of families
who opted for treatment outside the trial. As the trial
progressed, consultations that highlighted issues of
trial acceptability (such as crossover and study with-
drawal) were analysed for content and presentation of
information. Thematic analysis [36] was used to iden-
tify common or divergent themes, particularly focus-
ing on the impact of information delivered by
recruiters, on patients and parents. Individuals exhi-
biting contrasting views (negative cases) were studied
in detail to understand reasons underlying such differ-
ences [37]. Interview transcripts were imported into
NVivo 10 and analysed thematically in parallel with
the corresponding recruitment consultation, to ex-
plore the acceptability of trial methodology and deter-
mine feasibility of a full trial.
Fidelity checks
Intervention sessions were routinely audio-recorded,
with consent. We transcribed these recordings, re-
moved patient and clinician identifiable data and re-
moved the words “Graded Exercise Therapy” and
“activity management” to blind those rating the tran-
scripts to treatment allocation. Using the protocol, we
created a checklist of GET elements and activity man-
agement elements. Clinicians were asked to review the
blinded transcript against this checklist and then record
whether they thought it was a GET or activity manage-
ment session.
The Trial Steering Committee and the Data Safety
Monitoring Committee
The Trial Steering Committee (TSC) (who met
three times during the feasibility phase) were re-
sponsible for advising on trial methodology, review-
ing the progress of the study against the Stop-Go
criteria and advising whether the feasibility study
should proceed to the full trial. The Data Safety
Monitoring Committee (DSMC) met once during
the feasibility phase to review recruitment, reten-
tion, withdrawal rates and safety outcomes. Neither
the Trial Management Group (TMG), TSC nor the
DSMC analysed any patient-reported outcome data
by trial arm during the feasibility phase of the
study. The DSMC analyses of safety outcomes were
conducted by the study statistician, who took no
part in the decision to use the feasibility data in the
full trial.
Patient involvement
We consulted with the University of Bristol CFS/ME
Young Persons Advisory Group (YPAG) prior to the
study to gain feedback on aspects of trial design (tele-
phone recruitment) and the study documents.
Results
Between September 2015 and August 2016, 287
young people were assessed across the three sites
(for site details see below). Of these, 161 were eli-
gible for the study and 80 (49.7% of those eligible)
were recruited. Table 1 provides the baseline charac-
teristics of those recruited into MAGENTA. Seventy
percent of the participants were female, with a me-
dian age of 15 years, median illness duration of 15
months and median school attendance of 3.0 school
days per week. The baseline measures were nearly all
complete. Two participants reported that school
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attendance was not applicable, one of whom was re-
ceiving home tuition and one was not. One partici-
pant missed all items of the Chalder Fatigue scale.
Fourteen participants were missing all items of the
HADs anxiety and HADs depression subscales.
Interviews were conducted with 27 families from
Centre One. Twenty-six interviews were conducted
with parents (24 mothers, one father and one joint
interview with both parents) and 26 with young
people participating in the trial (10 male and 16 fe-
male). Three families cancelled interviews because
they were unavailable, one participant declined to be
interviewed on the day and one parent was unavail-
able for interview. Two participants had discontinued
their allocated treatment at the time of interview
(both assigned activity management). Participants
were asked if they were willing to be interviewed
alone but 21 chose to be interviewed with their par-
ent present. Ten families chose face-to-face interviews
(nine in their home and one at their local hospital);
14 were interviewed over the phone and three via
Skype. Families were interviewed at varying time
point in the treatment period, ranging from 3 to 35
weeks post randomisation.
Eligibility and recruitment
The feasibility of recruitment was assessed in all
three sites.
Centre One
Between 1 September 2015 and 31 August 2016, 272
young people attended clinic appointments of which
155 (57.0%) were assessed as being eligible. The
main reasons for exclusions were referral for psycho-
logical support at assessment (34), not diagnosed as
having CFS/ME (32) and being unable to attend fol-
low up (11). Of the 155 eligible, 78 (50.3%) con-
sented and were randomised to the study. The main
reasons families declined participation after discus-
sion with the researcher were preference for a spe-
cific treatment (19) and perceived study burden (12).
The number of participants randomised was there-
fore 78 out of the 263 assessed for the study (30%,
95% confidence interval 24%, 36%). Figure 2 de-
scribes the flow of young people screened and re-
cruited at Centre One
Centre Two
Centre Two was open to recruitment between Janu-
ary 2016 and 31 August 2016. Nine young people
were assessed within the service, three of whom
were ineligible (two were unable to attend follow-up
and one had severe CFS/ME). Of the six eligible pa-
tients, three declined before consent to contact and
one declined at the recruitment discussion. All three
patients cited the distance of travel to the service as
the reason for declining. Two participants consented
to the trial. See Additional file 1 for the CONSORT
diagram.
Centre Three
Centre Three started recruiting in January 2016. Six
participants were assessed within the service. Three
were not eligible for MAGENTA; reasons for exclu-
sion were referral to psychological services, previ-
ously seen in the service and too old. Three
participants were recruited. Clinicians were unable to
deliver treatment, deliver recruitment calls or collect
baseline data according to the protocol. Therefore,
Table 1 Baseline characteristics of participants
Outcome Median (25 percentile, 75 percentile) or n (%) n
Age in years 15.0 (12.5, 16.0) 80
Female 56 (70.0%) 80
Ethnicity; White or British 76 (95.0%) 80
Months since onset of symptoms 15.0 (10.0, 30.0) 80
School attendance, days per week 3.0 (1.0, 4.0) 77
Home tuition; yes 10 (12.5%) 80
SF36 Physical Function 55.0 (37.5, 72.5) 80
Chalder Fatigue 25.0 (22.0, 28.0) 79
Spence Children’s Anxiety Scale 32.0 (19.5, 47.0) 80
HADS Anxiety 8.0 (6.0, 13.0) 66
HADS Depression 8.0 (4.0, 11.0) 66
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the three patients were withdrawn from the trial but
continued to receive specialist medical care. See
Additional file 2 for the CONSORT diagram.
Provision and acceptability of patient information and
recruitment process
Participants provided positive feedback about being in-
volved in the research:
“it’s quite fun…you’re also helping other people with
CFS in the long run” (young person, ID108, activity
management)
Participants and their families felt the oral recruit-
ment consultation was acceptable, and felt they pro-
vided the “right level of information” in a
“straightforward” and “well explained” manner. Par-
ticipants indicated that the recruitment consultation
enabled them to ask further questions and “clarify”
what participation entailed.
The participants who read the patient information
leaflets found them acceptable. Some participants re-
ported that they could not remember or did not read
the information sheet and relied on the fact that their
parent(s) had read it:
Fig. 2 CONSORT diagram for Centre One
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“I didn’t read it too much but mum did and she looked
quite happy with it” (young person, ID29, activity
management)
The majority of parents and participants found the on-
line consent system (REDCap) acceptable and easy to
use. Most preferred this method of consent over paper
consent forms, but some found the online system more
difficult to use on a tablet or smartphone:
“I tried to do it on my phone but yeah, it was just far
too small on my phone … it was quite difficult [on a tab-
let] because obviously ticking, when you’re trying to like
tap the bits in the box, sometimes you press something
and it’s, yeah…it disappeared at one point” (mother,
ID65, activity management)
Retention
In the first 12 months of the study, 35 participants
were due to complete their six-month follow-up ques-
tionnaires. 91.4% (32) of participants completed their
6-month primary outcome measures. Three partici-
pants withdrew from research follow-up, for unknown
reasons.
At six months, of the 35 healthcare resource use
and work productivity questionnaires due to be
completed, 15 (42.9%) were returned. To maximise
response rate, we reduced and simplified these
questionnaires. We removed the adapted healthcare
resource use questions and the socioeconomic ques-
tions from the baseline questionnaire. We also re-
duced the level of detail required from participants
about their medication use (removing dosage and
route of administration), and changing the question
from a free text response, to a multiple-choice re-
sponse (with the option of “other” and free text).
The acceptability (satisfaction and adherence) of
intervention
All participants started the treatment that they were
allocated. Three out of the 40 participants in the ac-
tivity management arm (7.5%) and three out of the 40
participants in the GET arm (7.5%) discontinued
treatment early (defined as discontinuing treatment
within six months of randomisation). Participants
could indicate more than one reason for discontinu-
ing treatment. Reasons given were the following: pref-
erence for the other arm (4), not recovering in the
allocated arm (2), deteriorating in the allocated arm
(1), not wanting further clinical treatment with the
service (1).
One participant in the activity management arm
crossed over to the GET arm after six months of
treatment because of a preference for this treatment.
This family was interviewed shortly after joining the
trial; the participant was happy to continue to par-
ticipate at this time, but all three family members
(participant, mum and dad) discussed a preference
for the non-allocated treatment arm. This was
largely due to a feeling that they had already tried
similar techniques:
“I kind of wanted to be in the other, other side of the
trial […] because I’d already tried this side and it hadn’t
worked before, so I was sort of wondering if maybe like
the other side would work. But, I’m happy to try this
side [activity management] and see if it works better,
now I’m older kind of thing”(young person, ID35, activ-
ity management).
The mean (SD) number of appointments attended at
Centre One was similar between groups (activity man-
agement 9.7 (4.7), n = 37 and GET 9.6 (4.5), n = 39)
(note that data on number of appointments attended
was missing for two participants).
Participants and parents in both arms commented on
finding core aspects of the specialist CFS/ME care pack-
age beneficial, (such as sleep hygiene, referral to a psych-
ologist and information about diet) and the importance
of a positive and trusting relationship with their
clinician:
“[clinician] goes through a lot more than just the
exercise, [GET] like I have like issues with my diet
and stuff, and she looks at that. Does the whole
sleep… like she referred me to a psychologist so
there’s actually a lot more which I wasn’t expecting
for it to cover. Which is really good, like that’s helped
quite a lot” (young person, ID20, GET).
“It’s focussed a lot on sleep. […] she’s definitely moved
my sleep time and that’s been the most helpful part”
(young person, ID9, activity management).
Qualitative feedback supports the acceptability
overall of both intervention arms. Although some
families expressed initial anxiety about the prospect
of GET, most were satisfied that it would be man-
ageable, “flexible” and tailored to the individual:
“It’s been really flexible to meet his needs so erm,
the… the exercise initially it was increased because
[name] could cope with that at the time and it’s de-
creased with, you know, [name] needs changed… cause
he was coping with other things as well, and so erm, the
exercise has decreased to allow for that for the moment
and I’m very confident that when we go back [clinician]
will listen to everything he says and… and you know,
change it accordingly and appropriately really” (mother,
ID43, GET).
Some participants reported that the GET
programme required them to initially reduce the
amount of activity they were doing, and they found it
hard to “restrict” their physical activity. They wanted
to do more or did not realise how much physical
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activity they were already doing until they started to
monitor it via GET:
Interviewer: Have you been given … a level of activity
and exercise that you’re supposed to do every day?
Young person: I don’t like the level.
Mother: No. She wasn’t happy.
Young person: No, it’s not good.
Mother: Ballet is one of … that’s her number one
thing that she loves more than anything in life and
she’s had to cut back a lot on her ballet, which I
didn’t know they’d say that she had to do and she’s
really not very happy about it….
(mother and young person ID5, GET).
Participants were encouraged to build up slowly to
avoid a “boom and bust” pattern of physical activity.
Most reported feeling less tired generally when they had
established a manageable and consistent amount of ac-
tivity on a daily basis:
“It’s [GET] been helpful. I can certainly walk further
now without being as tired. It’s stopped me being
quite as lethargic, getting out every day, definitely,
and yeah, my fitness has improved” (young person,
ID25, GET).
Those in the activity management arm also found
the approach positive and helpful on the whole when
managing CFS/ME symptoms. They also highlighted
that “limiting” high level “red” activity could be chal-
lenging and frustrating, particularly in the run up to
school exams. Recording cognitive activity levels on
activity management sheets or the “ActiveME” App
was seen as onerous for some, although parents and
participants noted that overall activity management
had a beneficial effect on their CFS/ME:
“She’s now reading books, she’s now able to cope with
watching, you know, something on television that she
hasn’t seen before. She’s now coping with maths, – and
[name] is much happier I think” (mother, ID51, activity
management).
During the feasibility phase, Centre One started
to offer appointments via Skype so that young
people did not have to travel to appointments. Cli-
nicians felt that this could also be beneficial for
participants within the MAGENTA study. As such,
the MAGENTA protocol was amended to allow the
use of Skype, and this amendment was approved by
ethics.
Acceptability of the Fitbit [heart monitor, GET only]
The original intention was to provide every partici-
pant in the GET arm of the study with a Fitbit to
measure their heart rate, but this did not prove
feasible because fewer participants than anticipated
returned them. Therefore, the protocol was
amended so that clinicians taught young people to
manually measure their heart rate. Younger children
and those who were unable to measure their heart
rate were provided with a Fitbit (subject to avail-
ability). This was incorporated into the full trial
protocol.
Those randomised to GET reported that they
enjoyed using the Fitbit, often finding other func-
tionality such as sleep or steps monitoring useful in
addition to heart rate monitoring. Some participants
were keen to be randomised to GET so they could
use a Fitbit; “He just wanted the FitBit, that was all
he wanted” (young person, ID23,GET). One family in
the activity management arm bought a Fitbit for
their child shortly after joining the trial. However,
one participant found the Fitbit too uncomfortable
to wear at night; “Well it’s hard to wear during the
night because I’m on my hand a lot, and then it like
hits my bone” (young person, ID16, GET).
Fidelity of interventions
Twelve treatment sessions were sampled from Centre
One, selecting two sessions from each clinician at
random. One session was sampled from Centre Two.
Of the 13 sessions rated by clinicians blinded to
intervention, all were correctly identified as the allo-
cated treatment.
The feasibility and acceptability of accelerometers
Acceptability and feasibility were determined by the
amount of valid data supplied by participants [30].
Of those accelerometers returned, we looked at the
number of participants who provided valid data at base-
line, three and six months.
Table 2 Accelerometer valid wear time and non valid wear time (based on at least 500 min per day of data for at least 2 weekdays
and a weekend day)
Time-point Valid use, n (%) Non-valid use with some
data available, n (%)
Non-valid use with no
data available, n (%)
Total
Baseline 39 (66.1) 15 (25.4) 5 (8.5) 59
3 months 33 (63.5) 16 (30.8) 3 (5.8) 52
6 months 19 (42.2) 19 (42.2) 7 (15.6) 45
Brigden et al. Pilot and Feasibility Studies           (2019) 5:151 Page 10 of 18
Table 2 shows that at baseline, 39 participants
(66.1%) provided valid data. Of the 20 participants
(33.9%) who did not provide valid data, 5 (8.5%) did
not wear the accelerometer at all. Fifty-two partici-
pants returned an accelerometer at three months, of
which 33 (63.5%) provided valid data, while three
(5.8%) did not wear the accelerometer at all. At
six months, 45 participants returned an accelerometer;
19 participants (42.2%) provided valid data and seven
(15.6%) did not wear the accelerometer at all.
Participants had mixed views on the acceptability of
the accelerometer. Some participants didn’t mind
wearing it and felt: “No one can see it, um it was
very discreet it went under my clothes” (young per-
son, ID9, activity management). Others found it “a bit
un-comfy” (young person, ID5, GET) or “itchy” young
person, ID72, activity management) and would have
liked it to be more discreet; “I struggled a bit to find
baggy enough clothes to wear with it” (young person,
ID25, GET). Some participants had not told friends
about their CFS/ME and the accelerometer raised
unwanted questions; “I don’t like people asking ques-
tions all the time, about that sort of thing” (young
person, ID25, GET) and had the potential to make
their condition more visible to others; “So I did get a
few odd looks ‘What are you wearing?’” (young per-
son, ID20, GET). Some participants forgot to put the
belt back on in the morning, after swimming or a
shower; “I often forgot to wear it a few times” (young
person, ID29, activity management). Some participants
reported that they did not wear the accelerometer if
they felt it was not a “typical” week (young person,
ID129, activity management). To address these issues,
we amended the “Accelerometer information sheet” in
July 2016 to encourage participants to wear the accel-
erometer whether it was perceived as a typical week
or not.
Ethical amendments
There were three substantial ethical amendments; full
details can be found in Table 5 in Appendix 1 and a
summary is provided in Table 3.
Table 3 Summary of amendments
Amendment number, date of
ethics committee approval
Summary of amendment (see Appendix 1 for
full details of all substantial amendments)
1. 29 January 2016 Amendments were made to the consent to study forms
for parents of participants age 16–17:
Participants aged 16–17 did not need parents to consent
on their behalf; however, parents were being asked to
complete parental questionnaires and needed to provide
consent to this research procedure. A consent form for
parents/carers of young people aged 16–17 years was added.
Amendments were made to the consent to study forms:
We intended to use data collected during the feasibility
study for the full-scale trial. This was stated in the protocol
and the participant information sheets. The consent to study
form was updated to reflect this.
Amendments were made to the protocol:
We amended the protocol
to allow qualitative interviews via Skype.
Amendment were made to the consent to contact, and consent
to discussion forms:
Changed wording and field added.
2. 31 March 2016 Amendments were made to the protocol:
Amendments were made to protocol in response to reviewers’
comments upon the publication of the MAGENTA feasibility protocol.
This included changes to the background information, aims and
objective, the methods, adding stop-go criteria and safety outcomes.
3. 27 July 2016 Amendments were made to the health economics forms:
We amended the forms due to poor response rate. We developed a
second version of the baseline, 6-month and 12-month questionnaires.
The new forms continued to capture our primary outcomes.
Amendments were made to the protocol to document the closing down
the Cambridge Site:
We were unable to recruit from the Cambridge site and documented
the sites closure in the protocol.
Amendments were made to the protocol:
We changed wording in the protocol to provide further detail and
clarification in the background and methods sections.
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Feasibility criteria
The stop-go criteria (as reported in our protocol) are shown
in Table 4, with an assessment of whether the criteria were
met.
Discussion
This study has shown that it is feasible to conduct
an RCT investigating the effectiveness and cost-
effectiveness of GET compared to activity manage-
ment. Fifty percent of those who were eligible to
take part consented, and families accepted the novel
process of online consent, which enabled participants
to be recruited at home, reducing study burden.
Recruiters were trained in recruitment practice fol-
lowing scrutiny of audio-recorded recruitment dis-
cussions to ensure that families had sufficient and
balanced information to make a fully informed deci-
sion about participation. Response rate to the pri-
mary outcome was high, in contrast to collecting
accelerometer data and healthcare resource use and
work productivity data. A proportion of the acceler-
ometers (41.7% across the three time points) did not
contain valid data, and some participants did not
like the feel or look of the device, and the fact that
this made their condition visible to peers. However,
as accelerometer and healthcare resource use data
were not our primary outcome, this does not affect
the feasibility of conducting the full RCT. The quali-
tative data showed that some families had negative
perceptions of GET prior to joining the study. How-
ever, those that received GET reported that it was
acceptable, describing it as flexible, tailored and
manageable. Equally, participants found activity man-
agement acceptable. In both arms, some participants
disliked the initial restrictions on activity. All partici-
pants started their allocated treatment and less than
10% in each arm discontinued treatment, which is
generally considered acceptable [38].
This is the first study to conduct a trial comparing
GET and activity management for paediatric CFS/
ME, utilising RCT methodology with integrated
qualitative methodology. Qualitative data allowed us
to gather rich data about the trial process and inter-
vention and enabled us to improve the feasibility
and acceptability and to inform the design of an ad-
equately 0powered trial. Qualitative research meth-
odology embedded in adult RCTs has demonstrated
that exploring reasons for trial refusal and address-
ing patient concerns about terms that may be “mis-
understood” (such as “Graded Exercise Therapy”)
Table 4 Assessment of feasibility stop-go criteria
Stop-go criteria Assessment Stop-go-amend
Stop criteria: Less than 70 children and
adolescents have been recruited (∼ 70% of
the target) and if the qualitative data
collected suggest that recruitment cannot be
improved any further.
80 participants were recruited to the study. Go
Stop criteria: The 6-month follow-up is < 80%
and if the qualitative data suggest that follow-
up rates cannot be improved any further.
91.% (32) of participants completed their 6-
month primary outcome measures
Go
Stop criteria: Data suggest the interventions
are not acceptable to children and/or their
parents.
All participants started the treatment that they
were allocated. Three out of the 40
participants in the activity management arm
(7.5%) and three out of the 40 participants in
the GET arm (7.5%) discontinued treatment
early (defined as discontinuing treatment
within 6 months of randomisation).
Qualitative feedback supports the acceptability
overall of both intervention arms.
Go,
Amendments:
1. Treatment sessions could be carried out
via Skype.
2. Fitbits only offered routinely to younger
children and those unable to manually
measure their heart rate (subject to
availability).
Stop criteria: If the Data and Safety
Monitoring Committee (DSMC) and the Trial
Steering Committee (TSC) recommend the
trial is stopped for safety reasons.
The TSC, DSMC and TMG concluded that the
trial methodology and interventions were
acceptable and feasible, that no significant
changes needed to be made to either the
interventions or outcomes and that
recruitment should continue seamlessly to the
full trial. As participants have consented to the
use of data in the full trial, and neither the
interventions nor outcomes had changed; the
decision was made (with the support of the
DSMC, TSC and TMG) to use the outcome data
collected during the feasibility RCT in the full
trial.
Go
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can improve the consent process and in turn recruit-
ment [16, 32, 39]. Elements of The QuinteT Recruit-
ment Intervention (QRI) [32] were used during the
feasibility stage of the MAGENTA trial, e.g. regular
analysis of screening, recruitment and retention fig-
ures, audio-recording recruitment consultations and
conducting interviews with families and members of
clinical teams. The QRI approach was drawn upon
to explore trial processes, promote good communication
practices and understand preferences for treatment
impacting recruitment and retention. To our knowledge,
this was the first time elements of the QRI were used dur-
ing a feasibility trial recruiting young people.
Whilst this is a relatively small study, it was a
feasibility study, and a full scale adequately powered
study is underway. It became clear that it was not
feasible to run the study at one site (the site was
subsequently withdrawn from the study). The major-
ity of patients were recruited from one centre. This
centre covers a wide geographical region, provides
treatment through 10 different NHS trusts and is a
national referral service. As such, it provides assess-
ment and treatment for many more patients than
the two other centres involved in recruiting. There-
fore, recruitment to a multi-centre RCT, which
would increase the generalisability of findings, will
be challenging.
Recruitment rates for MAGENTA were higher than
our previous trial that evaluated other interventions
for young people with CFS/ME, where fewer than
30% of eligible young people were randomised [21],
suggesting potential participants found the trial and
the interventions acceptable. Wearing an accelerom-
eter made some participants feel that their CFS/ME
was more visible to friends at school, which may
have resulted in them feeling reluctant to wear the
device. This issue with acceptability of accelerome-
ters differs from previous school-based studies, which
have asked all pupils in a class to wear the device [40, 41].
The low rate of adverse events, which was similar in each
arm, is consistent with previous studies investigating exer-
cise treatments [42].
The TSC, DSMC and TMG concluded that the trial
methodology and interventions were acceptable and feas-
ible, that no significant changes needed to be made to ei-
ther the interventions or outcomes and that recruitment
should continue seamlessly to the full trial. As participants
have consented to the use of data in the full trial, and nei-
ther the interventions nor outcomes had changed, the de-
cision was made (with the support of the DSMC, TSC and
TMG) to use the outcome data collected during the feasi-
bility RCT in the full trial. The aims of the full trial were
to assess the effectiveness and cost-effectiveness of GET
versus AM.
Recommendations for a full study
 Results from this feasibility study show that this
RCT is feasible and can proceed to full trial. We
recommend the following changes, with the aim
that these changes will improve the recruitment
consultation, increase the response rates to
certain outcome measures (accelerometers and
health economics forms) and reduce the burden
of intervention sessions. The audio recordings of
recruitment consultations provided opportunities
for training recruiting staff. Training aimed to
address equipoise and improved the provision of
balanced study information and informed
consent.
 In response to qualitative feedback, we offered
recruitment consultations via Skype as well as
telephone to improve communication and the
participant’s experience.
 To address the low response rate to the resource
use and work productivity questionnaires, we
shortened the questionnaires with the aim of
making them more acceptable to participants.
 Feasibility and acceptability of accelerometers
were limited. We amended the participant
information leaflet following insights from the
qualitative research to minimise issues. Future
studies investigating paediatric CFS/ME may
consider alternative methods for collecting activity
data.
 To reduce burden on participants, we amended the
study protocol so that treatment sessions in both
arms could be carried out via Skype.
 It was not feasible to provide a Fitbit to every
GET participant. Therefore, the protocol was
amended so that clinicians taught young people
to manually measure their heart rate. Younger
children and those who were unable to measure
their heart rate were provided with a Fitbit
(subject to availability).
 Outcome data collected in the feasibility phase will
be used in the full trial analysis (internal pilot, as
outlined in the protocol).
Conclusions
Conducting an RCT investigating GET versus activity
management using novel techniques for recruitment
is feasible and acceptable for young people with CFS/
ME. As GET is recommended by NICE, an adequately
powered trial is necessary to test the effectiveness and
cost-effectiveness of GET for young people with CFS/
ME.
From the MAGENTA protocol [19]
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Appendix 1
Table 5 Summary of amendments
Amendment
number
Date of ethics
committee approval
Summary of amendment
1. 29/01/16 1. Consent to contact forms
MAGENTA 8-15 assent to contact 11082015 d0.6
MAGENTA 16-17 consent to contact 11082015 d0.6 *
MAGENTA parent carer consent to contact 11082015 d0.6 *
The above 3 documents currently have a box for “research ID” this needs to be changed to “consent ID”.
We are also changing the wording from “research nurse” to “research team”.
In addition, the 2 consent documents marked with * need a section where participants/ parents can
document the participants date of birth.
We would therefore like to change the above three documents to:
MAGENTA 8-15 assent to contact 18112015 d0.7
MAGENTA 16-17 consent to contact 18112015 d0.7
MAGENTA parent carer consent to contact 18112015 d0.7
2. Consent to study forms for parents of participants age 16-17
Participants aged 16-17 do not need parents to consent on their behalf; however, parents are being asked
to complete parental questionnaires and do need to provide consent to this research procedure. We have
therefore designed the consent form:
MAGENTA parent carer consent to study (16-17) 18112015 d0.1
3. Consent to study forms
MAGENTA 16-17 consent to study 18112015 d0.5
MAGENTA parent carer consent to study 18112015 d0.5
We will use data collected during the feasibility study for the full scale trial. We need participants to give
their consent and will now include the wording “I agree that data collected about me can be used in the
full trial”. We are also changing the wording from “research nurse” to “research team”.
See new forms below:
MAGENTA 16-17 consent to study 23102015 d0.6
MAGENTA parent carer consent to study 23102015 d0.5
This info has also been included in: MAGENTA parent carer consent to study (16-17) 18112015 d0.1
4. Consent to discussion
MAGENTA 8-15 assent to record discussion 18112015 d0.7
MAGENTA 16-17 consent to record discussion 18112015 d0.7
We are changing the wording from “research nurse” to “researcher”.
Clearer instruction on how to complete the form have been provided with the line “Please answer the
following questions by circling ‘yes’ if you agree”.
The line “I confirm that I would like to hear more information about this study” had been removed
because it is unnecessary.
“I understand that I can switch off the recorder or stop the discussion without having to give a reason”.
The wording of this line has been amended to make it more child-friendly.
The parental consent box has been removed from the 16-17 consent form, because it is unnecessary.
5. Protocol
We may carry out qualitative interviews via Skype. We have therefore added the following sentence to
the protocol:
“Interviews will take place in clinic, in the participant’s home or via Skype.”
The wording “special clinical psychologist” has been changed to “specialist psychologist” in line with the
services practice.
2. 31/03/16 The following amendments were made to the protocol:
1. Additional background information has been included. This provides further clarification on the current
evidence based and better defines the treatments. The protocol has been changed from:
“NICE recommends that children with CFS/ME are offered either CBT, Graded Exercise Therapy (GET) or
activity management effective in adults with CFS/ME but there is no evidence for the effectiveness or
cost-effectiveness for paediatric CFS/ME. There is also limited evidence on the acceptability of GET for chil-
dren with CFS/ME or on the best method for delivering GET in terms of intensity (frequency of sessions)
and length of treatment (number of sessions and length of time for follow up).”
to:
“NICE recommends that children with CFS/ME are offered either Cognitive Behavioural Therapy (CBT),
Graded Exercise Therapy (GET) or Activity Managemen t[5]. GET stabilises physical activity levels, before
gradually increasing at a manageable rate. Activity management establishes a baseline for all activity
(mainly cognitive, such as school and homework, in children and adolescents) which is then increased [5,
7]. There is good evidence for the effectiveness of CBT in children with CFS/ME [8–10]; however, there is
no evidence for the effectiveness of GET in children although GET is moderately effective in adults [11].
There is also limited evidence on the acceptability of GET for children with CFS/ME or on the best
method for delivering these interventions in terms of intensity (frequency of sessions) and length of
intervention (number of sessions and length of time for follow up).”
2. The aims and objectives have been re-worded to offer more specific details. The protocol has been
changed from:
• To investigate the recruitment process including eligibility assessment, the recruitment interview and the
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Table 5 Summary of amendments (Continued)
Amendment
number
Date of ethics
committee approval
Summary of amendment
views of children and parents about the recruitment process.
• Assess the number of eligible children, the number of children approached, the number recruited and
the number retained in the first 6 months of the study.
• To assess issues of retention and interviewing those who drop out of the study.
• Assess the acceptability (satisfaction and compliance) of graded exercise therapy and activity
management.
• Assess the feasibility and acceptability of using accelerometers to measure physical activity in children
with CFS/ME.
• Evaluate whether the two treatments are distinct and being delivered in a consistent manner across
centres.
to:
• Assess the number of eligible children, the number of children approached, the number recruited and
the number retained in the first 6 months of the study.
• Identify barriers and facilitators to trial recruitment with a view to addressing barriers where possible.
• Explore issues of retention and understand why people drop out of the study.
• Assess the acceptability (satisfaction and adherence) of GET and activity management.
• Assess the feasibility and acceptability of using accelerometers to measure physical activity in children
with CFS/ME.
• Evaluate whether the two interventions are distinct and being delivered in a consistent manner across
centres.
3. The protocol previously stated that the recruitment discussion would be carried out by a “research
nurse”. This has been amended to enable any trained member of the research team to undertake these
calls, therefore the wording is more generic e.g. “member of the research team” or “the recruiter”.
4. The protocol currently states that recruitment discussion will be carried out over the phone or face-to
face. We have updated the protocol to indicate that the recruitment discussion may also take place over
Skype. This is because the service is routinely using Skype and potential participants and their parents
have requested this.
5. The protocol previously stated that activity management would be carried out by CFS/ME specialists
that are not physiotherapists. The protocol has been amended to state that any activity management
trained CFS/ME specialist, including physiotherapists, may deliver this intervention.
6. The protocol previously stated that graded exercise therapy (GET) would only be carried out by GET-
trained physiotherapists. The protocol has been amended to state that any CFS/ME specialist who has
been trained in GET (including occupational therapists, nurses, psychologists) may deliver this
intervention.
7. The protocol previously stated: In both treatment arms, children, their parents/carers and the clinician
providing treatment will choose the number of follow-up sessions (between 8 and 12) and the frequency
of appointments (every 2–6 weeks) within a maximum length of treatment of 1 year.
The amended protocol offers estimations for frequency and duration and clarifies that trial intervention
should be carried out in line with standard clinical practice:
In both treatment arms, children, their parents/carers and the clinician providing treatment will choose
the number of follow-up sessions (estimated to be between 8 and 12) and the frequency of appoint-
ments (every 2–6 weeks), in line with standard clinical practice.
8. We have changed the protocol to indicate that therapist may offer intervention sessions via Skype. This
is because this has become routine clinical practice and patients and parents have requested this. In this
instance, sessions will still be audio recorded. Children will be asked to provide consent to the audio
recording of treatment session on paper forms, to be returned by post, or on-line via the redcap system.
9. The protocol previously stated:
We will assume that the intervention is not acceptable for participants who DNA or have late
cancellations for > 25% of follow-up appointments.
On the recommendation of the trial management group, this has been changed to:
We will assume that those who did not attend (or cancelled within 24 h) three or more consecutive
appointments or 50% of appointments did not find the interventions acceptable.
10. The outcome measure EQ-5D-5 L has been changed to EQ-5D-Y. The EQ-5D-Y is designed and vali-
dated for use with younger populations. Both the trial management group and trial steering committee
advised that the EQ-5D-Y should be used in this trial.
11. The trial management group recommended that wear diaries should only be sent to participants in
the initial stages of the study to determine the validity of accelerometer data. Beyond this, the diaries
would be an additional burden for participant with little added benefit. The protocol previously stated:
Participants will be asked to complete a log of wear time (time worn and time taken off) which can be
integrated with their activity/exercise diaries.
This has been updated to:
In the initial stage of the study approximately 10 participants will be asked to complete a log of wear
time (time worn and time taken off). This wear diary data will be compared against accelerometer data to
check for the validity/ reliability of using accelerometers with young people with CFS/ME.
12. Further details about the analysis of accelerometer data have been provided. The following have been
added:
The accelerometer data will be processed to identify mean minutes of sedentary, light and moderate to
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Table 5 Summary of amendments (Continued)
Amendment
number
Date of ethics
committee approval
Summary of amendment
vigorous intensity physical activity per day using established accelerometer cut-off points and protocols16
24 . The mean accelerometer counts per minute, which provides an indication of the volume of physical
activity in which the participant engages, will also be calculated using established methods.
13. We have changed the protocol to indicate that the qualitative interviews will also be offered over
Skype. If the interview takes place over Skype,s children will be asked to provide consent on paper forms,
to be returned by post, or on-line via the redcap system.
14. Stop-go criteria for the study has been added:
Proposed stop criteria for MAGENTA: We will not proceed to the full trial if at 12 months (end of August
2016), one of the following is true:
• We have recruited less than 70 children (~ 70% of the target specified) AND if the qualitative data
collected suggests that we cannot improve recruitment by changing recruitment methods
• The 6-month follow-up is less than 80% and AND if the qualitative data suggests we cannot improve
follow-up.
• The qualitative data suggests the interventions are not acceptable to children and/or their parents.
• If the DSMC recommend the trial is stopped for safety reasons and if the TSC agree with this decision.
15. Further details about safety analysis have been added. The following are now detailed:
Safety outcomes
For safety outcomes, we will prospectively collect serious and non-serious adverse events defined as any
clinical change or illness reported at clinic or postal follow-up. We will define a serious deterioration in
health as: a decrease ≥ 20 in SF-36-PFS or scores of “much” or “very much worse” on the Clinical Global
Impression scale; clinician reported serious deterioration in health; or withdrawal from treatment because
of feeling worse. Safety outcomes will be analysed by the Data and Safety Monitoring Committee (DSMC)
and reported to the Trial Steering Committee.
Frequency of analyses
The first interim safety analyses will be at 10 months (before the trial transitions from the feasibility to full
phase). The DSMC will decide on the second safety analyses which may be at 18 months or when 50% of
children have been recruited. The safety analyses will be used to ensure that neither intervention arm is
having a detrimental effect. These analyses will only investigate safety outcomes and will be conducted
by an independent statistician with results provided to the Data and Safety Monitoring Committee.
Data and Safety Monitoring Committee (DSMC): (3 independent experts in CFS/ME, statistics and trials)
will have unblinded access to the data to make recommendations to the TSC on whether there are safety
reasons to stop the trial.
16. The protocol previously gave a target sample size for all three sites combined. The new protocol
offers a target sample-size for each site.
17. The protocol previously stated that the feasibility study would recruit for 13 months; this has been
amended to 12 months.
3. 27/07/16 1.Changes to wording in the protocol
• We have updated the Background section of out protocol to incorporate further studies in the field. We
have changed “no evidence” to “little evidence”, and we have now included references to Lim and
Lubitz (2002), Gordon and Lubitz (2009) and Gordon et al (2010).
• We have corrected a typo “on” to “of”
• We have changed the wording through from “child” or “children” to know say “Child and adolescent” or
“children and adolescents” or “young person” or “young people” or “participants.” This more accurately
describes our study population.
• We have made additional comments about the exclusion criteria section, to provide further definition
and explanation. This has changed from: “Children will be excluded if they:
- are too severely affected to attend hospital appointments (and require a domiciliary assessment);
- are referred for CBT at their first clinical assessment;
- are unable to attend follow-up appointments; “
To:
“Children and adolescents will be excluded if they are severely affected. NICE defines severe CFS/ME as
individuals who are unable to do activity for themselves, or carry out minimal daily tasks only, they have
severe cognitive difficulties and depend on wheelchair for mobility 5; or are referred for CBT at their first
clinical assessment or are unable to attend clinical sessions. Eligibility assessment will be carried out by
the clinician at assessment and confirmed by the recruiting researcher.”
2. Amendments to health economics forms
We have had a poor response rate to our health economic forms, and we want to address this issue
during the feasibility stage. We have been working closely with our Trial Management Group and our
Health Economists and have developed a second version of the baseline, 6- month and 12-month ques-
tionnaires. The new forms continue to capture our primary outcomes. However, we have removed un-
necessary questions, streamlined others, changed wording and have re-structured the forms to make
them more user-friendly. We have attached both the original versions and second versions of these
forms.
We have changed the wording in the protocol to reflect changes. From:
“Both parents will be asked to complete 3 inventories on-line at baseline, 6 and 12 months follow-up
including:
socioeconomic status (baseline only); an adapted 4 item Work Productivity and Activity Impairment
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